CA3017359A1 - Crystalline salt forms - Google Patents

Crystalline salt forms Download PDF

Info

Publication number
CA3017359A1
CA3017359A1 CA3017359A CA3017359A CA3017359A1 CA 3017359 A1 CA3017359 A1 CA 3017359A1 CA 3017359 A CA3017359 A CA 3017359A CA 3017359 A CA3017359 A CA 3017359A CA 3017359 A1 CA3017359 A1 CA 3017359A1
Authority
CA
Canada
Prior art keywords
crystalline form
theta
pattern
compound
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3017359A
Other languages
English (en)
French (fr)
Inventor
Scott M. Duncan
Martin P. Redmon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stealth Biotherapeutics Inc
Original Assignee
Stealth Biotherapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Biotherapeutics Corp filed Critical Stealth Biotherapeutics Corp
Publication of CA3017359A1 publication Critical patent/CA3017359A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C07C55/07—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3017359A 2016-03-11 2017-03-10 Crystalline salt forms Pending CA3017359A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662307095P 2016-03-11 2016-03-11
US62/307,095 2016-03-11
PCT/US2017/021790 WO2017156403A1 (en) 2016-03-11 2017-03-10 Crystalline salt forms

Publications (1)

Publication Number Publication Date
CA3017359A1 true CA3017359A1 (en) 2017-09-14

Family

ID=59789873

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3017359A Pending CA3017359A1 (en) 2016-03-11 2017-03-10 Crystalline salt forms

Country Status (6)

Country Link
US (3) US10683326B2 (enExample)
EP (1) EP3426675B1 (enExample)
JP (1) JP7038675B2 (enExample)
CN (2) CN115160402A (enExample)
CA (1) CA3017359A1 (enExample)
WO (1) WO2017156403A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115160402A (zh) 2016-03-11 2022-10-11 隐形生物治疗公司 结晶盐形式
WO2018187400A1 (en) 2017-04-05 2018-10-11 Stealth Biotherapeutics Corp. Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
CA3095869C (en) 2018-04-02 2025-10-21 Stealth Biotherapeutics Inc. CRYSTALLINE DIPEPTIDES USEFUL IN THE SYNTHESIS OF ELAMIPRETIDE

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2085865T3 (es) * 1988-06-30 1996-06-16 Astra Ab Analogos de dermorfina, sus metodos de preparacion, composiciones farmaceuticas, y metodos de tratamiento terapeutico que los emplean.
SI2656854T1 (sl) 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
US20120178762A1 (en) * 2006-12-15 2012-07-12 Warner Chilcott Company, Llc Compositions of azimilide dihydrochloride
EP3563862B1 (en) * 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
WO2010125004A1 (en) 2009-04-29 2010-11-04 Nerviano Medical Sciences S.R.L. Cdk inhibitor salts
SMT202300433T1 (it) * 2009-08-24 2024-01-10 Stealth Biotherapeutics Inc Peptide per l'uso nella prevenzione o nel trattamento della degenerazione maculare
CA2786280A1 (en) * 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
EP2848628A1 (en) * 2010-01-25 2015-03-18 Cornell University Aromatic-cationic peptides and uses of same
WO2011116007A1 (en) * 2010-03-15 2011-09-22 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
WO2011156473A1 (en) 2010-06-09 2011-12-15 Abbott Laboratories Crystalline forms of kinase inhibitors
HK1204988A1 (en) * 2012-02-22 2015-12-11 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
CN110339339A (zh) * 2013-03-01 2019-10-18 康德生物医疗技术公司 治疗线粒体疾病的方法
WO2015060462A1 (en) * 2013-10-23 2015-04-30 Kaneka Corporation Tetrapeptide compound and method for producing same
JP6634016B2 (ja) 2013-12-03 2020-01-22 アムジエン・インコーポレーテツド Ｎ−（４−（（３−（２−アミノ−４−ピリミジニル）−２−ピリジニル）オキシ）フェニル）−４−（４−メチル−２−チエニル）−１−フタラジンアミンの薬学的に許容される塩の結晶形態及びその使用
US10112976B2 (en) * 2014-06-30 2018-10-30 Flamma S.P.A. Process for the production of D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide
WO2016004067A1 (en) * 2014-06-30 2016-01-07 Stealth Biotherapeutics Corp Aromatic-cationic peptide formulations, compositions and methods of use
AU2015287583A1 (en) * 2014-07-10 2017-02-02 Rhode Island Hospital Treating arrhythmia with mitochondrial-targeted antioxidants
EP3800192A1 (en) 2015-03-06 2021-04-07 Stealth Biotherapeutics Corp Processes for preparing pharmaceutically relevant peptides
CN115160402A (zh) 2016-03-11 2022-10-11 隐形生物治疗公司 结晶盐形式
US10961273B2 (en) * 2016-08-16 2021-03-30 Stealth Biotherapeutics Corp. N-carboxyanhydride-based-scale synthesis of elamipretide
WO2018187400A1 (en) 2017-04-05 2018-10-11 Stealth Biotherapeutics Corp. Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2
US10676506B2 (en) * 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
CA3095869C (en) * 2018-04-02 2025-10-21 Stealth Biotherapeutics Inc. CRYSTALLINE DIPEPTIDES USEFUL IN THE SYNTHESIS OF ELAMIPRETIDE

Also Published As

Publication number Publication date
EP3426675A1 (en) 2019-01-16
US10683326B2 (en) 2020-06-16
JP2019512542A (ja) 2019-05-16
JP7038675B2 (ja) 2022-03-18
WO2017156403A1 (en) 2017-09-14
EP3426675B1 (en) 2020-08-05
US20210047368A1 (en) 2021-02-18
CN115160402A (zh) 2022-10-11
US20230279049A1 (en) 2023-09-07
US11555053B2 (en) 2023-01-17
CN109476700A (zh) 2019-03-15
US20190382442A1 (en) 2019-12-19
US12252553B2 (en) 2025-03-18
EP3426675A4 (en) 2019-10-16

Similar Documents

Publication Publication Date Title
US12252553B2 (en) Crystalline salt forms
US11261213B2 (en) Crystalline bis- and tris-hydrochloride salt of elamipretide
JP2008509953A (ja) ４−［［（７ｒ）−８−シクロペンチル−７−エチル−５，６，７，８−テトラヒドロ−５−メチル−４−６−オキソ−２−ピペリジニル］アミノ］−３−メトキシ−ｎ−（１−メチル−４−ピペリジニル）ベンズアミドの水和物及び多形、その製造方法、並びにその薬物としての使用
CN105111117A (zh) 制备截短侧耳素的工艺
ES2879294T3 (es) Formas polimórficas de Belinostat y procesos para la preparación de las mismas
US11325943B2 (en) Crystalline salt forms of SBT-20
TW201718516A (zh) 組蛋白去乙醯酶抑制劑之晶形
US7132541B2 (en) Crystalline fluoroquinolone arginine salt form
US12084441B2 (en) Salts of a compound and the crystalline forms thereof
JPH0253795A (ja) 新規なエステル
US20150239890A1 (en) Crystal of n-[2-(amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide
CN101098850B (zh) 西布曲明的无机酸盐
ES2974331T3 (es) Sales de (R)-9-(2,5-difluorofenetil)-4-etil-2-metil-1-oxa-4,9-diazaspiro[5.5]undecan-3-ona
CN114728982A (zh) 固体形式的s1p-受体调节剂
JP2005511611A (ja) インテグリン受容体拮抗薬のアミン塩
WO2006023676A1 (en) Clopidogrel napsylate salt
HK40003395B (en) Crystalline salt forms
JP2013531662A (ja) カルシウム模倣化合物の新規多形
CN112876510A (zh) 一种磷酸酯类多环化合物及其药物组合物和用途
EP1509519B1 (en) Crystalline fluoroquinolone arginine salt form
WO2017144598A1 (en) Cocrystals of lorcaserin
CN107778265A (zh) 具有免疫调节作用的杂环衍生物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220307

EEER Examination request

Effective date: 20220307

EEER Examination request

Effective date: 20220307

EEER Examination request

Effective date: 20220307

EEER Examination request

Effective date: 20220307

EEER Examination request

Effective date: 20220307

EEER Examination request

Effective date: 20220307